Fibroblast Growth Factor-21 (FGF-21) enhances mitochondrial functions and increases the activity of PGC-1&#945; in human dopaminergic neurons. by Maiorana, F.
  
UNIVERSITÀ DEGLI STUDI DI PALERMO 
DIPARTIMENTO DI BIOMEDICINA SPERIMENTALE E 
NEUROSCIENZE CLINICHE (BIONEC) 
 
Dottorato in Fisiopatologia Neurosensoriale 
 
Fibroblast Growth Factor-21 (FGF-21) enhances 
mitochondrial functions and increases the activity of PGC-1α 
in human dopaminergic neurons. 
Il Fattore di crescita FGF-21 potenzia  le funzioni mitocondriali ed 
incrementa l’attività di PGC-1α in neuroni dopaminergici umani. 
 
 
Settore scientifico disciplinare BIO/09 
 
 
TESI DI  
DOTT.SSA  
FRANCESCA MAIORANA 
 
 
 
 
 
COORDINATORE DEL DOTTORATO 
PROF. GIUSEPPE FERRARO 
TUTOR  
PROF. NATALE BELLUARDO 
 
 
XXIV CICLO - ANNO ACCADEMICO 2012-2013
Table of Contents 
Summary .......................................................................................... 1 
Background ...................................................................................... 1 
Fibroblast Growth Factor 21 ........................................................................................................ 1 
Physiological and Pharmaceutical actions of FGF-21 ................................................................. 4 
FGF-21 induces PGC-1α .............................................................................................................. 8 
Peroxisome proliferator-activated receptor c co-activator protein-1α (PGC-1α)......................... 9 
Parkinson’s Disease and neuroprotective effects of PGC-1α in dopaminergic neurons ............ 13 
Aims ................................................................................................ 17 
Materials and Methods .................................................................. 18 
Cell culture ................................................................................................................................. 18 
Animals ...................................................................................................................................... 18 
Immunoblotting .......................................................................................................................... 19 
Immunohistochemestry .............................................................................................................. 20 
Immunoprecipitation .................................................................................................................. 21 
Luciferase Assay ........................................................................................................................ 21 
NAD+/NADH levels .................................................................................................................. 22 
Real-time analyses of mitochondrial respiratory capacity in human dopaminergic neurons ..... 22 
Mitochondrial DNA copy number ............................................................................................. 22 
Electron microscopy and mitochondrial density analysis .......................................................... 23 
Animal experiments ................................................................................................................... 24 
Results ............................................................................................ 25 
FGF-21 is able to increase levels and deacetylation of PGC-1α in cultured human 
dopaminergic neurons ................................................................................................................ 25 
FGF-21 increases Nampt and NAD+ levels and SIRT-1 in the dopaminergic neurons ............ 27 
FGF21 increases mitochondrial antioxidants in human dopaminergic neurons ........................ 30 
FGF-21 stimulates mitochondrial respiratory capacity of human dopaminergic neurons ......... 32 
FGF-21 is expressed in the midbrain and microglia cells .......................................................... 34 
Discussion ...................................................................................... 38 
Conclusions .................................................................................... 42 
References ...................................................................................... 43 
  
Summary 
 
The Fibroblast Growth factor 21 (FGF-21) is a member of the FGFs family and 
forms a subfamily with FGF-19 and FGF-23. These three unique FGFs are able to 
function in an endocrine manner.  FGF-21  plays  important roles in metabolic regulations 
including, glucose homeostasis, energy expenditure, and lipid metabolism;  it is widely 
express in metabolic tissues such as liver, adipose tissue, muscle, and pancreas. Thus 
FGF-21 has been largely studied due to its physiological functions,  but  very little is 
known yet about the expression of FGF-21 in the brain, and its possible actions in the 
Central Nervous System (CNS). FGF-21 exerts also its functions  through the 
involvement of other factors, modulating the expression of specific proteins, that activate 
downstream pathways in response to certain stimuli. One of the main target of FGF-21 is 
the Peroxisome proliferator-activated receptor co-activator protein-1α (PGC-1α), a 
transcriptional co-activator that is increased in several tissues by FGF-21. PGC-1α is a 
major regulator of mitochondrial functions,  biogenesis, and antioxidant response and  it 
was suggested as a therapeutic target in Parkinson’s Disease (PD). According to this, 
recently Mudò et al. have demonstrate, the neuroprotective effect of PGC-1α, due to its 
antioxidant actions, in an animal model of PD. PGC-1α is regulated by both 
transcriptional and posttranslational events, as deacetylation of specific lysine residues 
performed by specific deacetilase like SIRT-1. These transcriptional and posttranslational 
modifications  involve  in addiction the action of growth factors. Therefore, on the basis 
of these observations, using different approaches, the aim of present study was to 
investigate the possible interactions between the growth factor FGF-21 and PGC-1α in 
dopaminergic neurons, and its possible expression in the brain. We demonstrate here that 
FGF-21 increases the levels of  PGC-1 α and its transcription, enhancing the gene 
promoter activity in human dopaminergic cell culture. Moreover  in these cells FGF-21 is 
able to increase the activity of PGC-1α and elevate mitochondrial antioxidants. The 
activation of PGC-1α by FGF-21 occurs  via the NAD+-dependent deacetylase SIRT-1 
subsequent to an increase in the enzyme nicotinamide phosphoribosyltransferase 
(Nampt), that is the is the rate-limiting enzyme in NAD
+
 biosynthesis.  The increase of  
mitochondrial antioxidant enzymes levels is accompanied by enhanced mitochondrial 
respiratory capacity,  as shown in real-time analyses of living cells, but not by an increase 
of the number of these organelles in FGF-21 treated cells. Our  results suggest that    
  
FGF-21 enhances in human dopaminergic neurons,  the  mitochondrial activity, by 
inducing the increase of levels and activity of PGC-1α, via SIRT-1. In vivo,  to 
investigate  if FGF-21 was locally  produced in the brain, we asses FGF-21 levels in  
some  brain areas using immunoblot analysis. We observed that FGF-21 is expressed in 
several brain regions, such as the cortex, hippocampus, striatum and substantia nigra.  
Next, in order to identify brain cells type involved in FFG-21 production ,  we performed 
immunohistochemistry assays, using substantia nigra sections from  adult rats brain 
treated with Kainic acid, that induces an excitotoxic damage. These assays reveal that 
neither the dopaminergic neurons nor astrocytes are involved in the FGF-21 production, 
microglia cells rather express  the growth factor, suggesting a role of FGF-21 in the 
neuroimmunological response.    
  Taken together these results show  that dopaminergic neurons respond to FGF-21 
by enhancing the mitochondrial capacity and altering gene pathways regulated by PGC-
1α, and that FGF-21 is expressed in the brain by microglial cells, probably following a 
damage that can active a neuroimmunological  response.  
These findings can open the way to study the potential benefits   of  FGF-21 
treatment in different neurological disorders such as in  Parkinson’s Disease
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Background 
 
Fibroblast Growth Factor 21 
 
Fibroblast Growth Factor 21 (FGF-21) was first isolated from mouse embryo DNA, 
its murine gene is located in chromosome 7, while human FGF-21 gene is located in 
chromosome 19 (Nishimura T. et al, 2000; Homo Sapiens Gene ID 2012). FGF-21 is a 
209-amino acid-long protein with an N-terminal signaling peptide, that after the cleavage, 
results a mature protein with 181 amino acid (w20 kDa) (Huating L. et al, 2013); it is 
classified as a Fibroblast Growth Factor based on its structure, because it contains a 
common domains and shares 10%–30% sequence identity with other Fibroblast Growth 
Factors. 
 
 
Fig.1- FGFs gene family-The filogenetic subdivision based on 
evolutionary relationship. (Cicione et al, 2012) 
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The Fibroblast Growth Factor superfamily, named by its ability to stimulate 
fibroblast proliferation, contains 22 proteins, divided into subfamilies, based on their 
structural similarities and modes of action. The Gene family can be divided into three 
subfamilies: the intracellular FGFs (FGF11/12/13/14), the endocrine FGFs (FGF15/19/ 
21/23), and the paracrine FGFs (others) (Long Y. et al, 2011; Itoh and Ornitz, 2008; 
Kuro-o, 2008) (Fig.1). All FGFs are essential for embryonic development and that 
function postnatal as homoeostatic factors, in the response to injury, in the regulation of 
electrical excitability of cells and as hormones that regulate metabolism. In humans, FGFs 
signaling is involved in developmental, neoplastic, metabolic and neurological diseases. 
All FGFs act through binding extracellularly to four cell surface tyrosine-kinase FGF 
receptors (FGFRs 1–4) (Zhang X. et al, 2006; Krejci P. et al, 2009; Beenken A. et al, 
2009). FGFRs genes have been identiﬁed in humans and mice and encode receptor 
tyrosine kinases (ca. 800 amino acids). These receptors contain an extracellular ligand-
binding domain with three immunoglobulin domains (I, II, and III) that need to the 
recognition; a transmembrane domain, and a split intracellular tyrosine kinase domain. 
FGFRs are expressed on many diﬀerent cell types and regulate key cell functions, such as 
proliferation, diﬀerentiation, and survival. Unlike other growth factors, FGFs act in 
concert with heparin or heparan sulfate proteoglycan (HSPG) to activate FGFRs and 
induce the pleiotropic responses that lead to a variety of cellular response. As such others 
FGFs, also the activity of FGF-21 is mediate by interaction with FGF receptors, but FGF-
21, like others components of the same sub-family (FGF-19 and FGF-23), is not able to 
directly bind to the FGFRs,  in fact, to interact with receptors, it needs a cofactor named 
β-Klotho. The cofactor β-Klotho is single-pass trans-membrane protein predominantly 
expressed in metabolic organs like Liver, White Adipose Tissue (WAT), Brown Adipose 
Tissue (BAT) and Pancreas (Ito S. et al 2000). Moreover the cofactor is important for the 
FGF-21 specificity of the target cells (Ogawa Y. at al 2007, Suzuki M. et al 2007).          
β-Klotho can interact with FGFR1, 2, 3 and 4, and FGF-21 has been reported to activate 
β-Klotho-FGFR1. FGFR1 is a strong candidate receptor for FGF-21 because interacts 
with β-Klotho more strongly than FGFR2 and 3. The FGFR1 is expressed broadly, but β-
Klotho and FGF-21 expression is more restricted to metabolic tissues such as brown 
adipose tissue, WAT, liver, pancreas, muscle and the intestinal tract, this could explain 
the metabolic effects induced by FGF-21. The FGF-21–β-Klotho–FGFR complex acts by 
inducing a number of downstream signals such as MAP kinase phosphorylation, RAF1, 
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AKT1 and STAT (Ogawa Y. at al 2007,Kharintonenkov A. and Shanafelt AB, 2008).     
β-Klotho plays an important role in FGF-21 actions, it is required for FGF-21 effects in 
growth and metabolism. Studies shown that in Knock Out (KO)-β-Klotho mice were lost 
every effect of FGF-21action in adipose tissue. The strongly expression of β-Klotho  in 
liver, adipose tissue and pancreas, can explain why the main effects of FGF-21 have been 
observed in these tissues (Fig.2) (Ito S. et al, 2000). FGF-21 has been described as an 
endocrine hormone due to its physiological effects on metabolism  in several districts; 
these beneficial metabolic actions   may also be associated to pharmacological effects, in 
diseases that affect these and others  organs. 
 
 
 
 
 
 
 
 
Fig. 2- Schematic representation of FGF-21 
actions, mediate by β-Klotho co-factor in 
adipocytes. 
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Physiological and Pharmaceutical actions of FGF-21 
 
FGF-21 is express in metabolic tissues and has several metabolic functions: it is 
able to regulate glucose uptake and insulin homeostasis, to influence fatty acid 
metabolism, to control LDLR levels and lipoprotein, to improve insulin sensitivity, and to 
preserve β-cell functions in diabetic animal models (Iglesias et al, 2012). FGF-21 is 
classified a growth factor with  “hormone-like” effect, in fact together with FGF-19 and 
FGF-23 compounds the “FGFs endocrine subfamily”.FGF-19 (the human ortholog of 
murine FGF-15) is expressed in the intestine and regulates bile acid synthesis in the liver 
in both rodents and humans (Inagaki T. et al, 2005; Lundåsen T et al, 2006). FGF-23 is 
produced in bone tissue and regulates phosphate and vitamin D metabolism via effects on 
the kidney (Fukumoto S. and Yamashita T., 2007). FGF-21 is expressed predominantly in 
the liver, in adipose tissue, pancreas and skeletal muscle (Muise ES. et al, 
2008;Nishimura T. et al, 2000;Wente W. et al, 2006; Johnson CL. et al, 2009).The 
expression of FGF-21 is regulated by different transcriptional factors, such as peroxisome 
proliferator-activated receptor A (PPARA) in the liver (Badman MK. Et al 2007; 
Hondares E. et al, 2010) and proliferator-activated receptor gamma (PPARG) in 
adipocytes (Wang H. et al, 2008), respectively  in response to stimuli like fasting, feeding, 
and cold. Its actions on metabolism are evident both in the fed and fasted state, but are 
most prominent during fasting.  In this case the induction of FGF-21 in the liver is 
mediate by the peroxisome proliferator-activated receptor a (PPARα); it is a nuclear 
receptor activated by fatty acids and the fibrate class of hypolipidemic drugs (Badman et 
al. 2007; Inagaki et al. 2007; Lundasen et al. 2007). PPARα binds directly to the FGF-21 
gene promoter to induce its transcription (Inagaki et al. 2007). In the adipose tissue the 
FGF-21 expression is induced  by PPAR-γ and by a  c-AMP-mediate pathway, which 
regulate the gene transcription stimulated by noradrenalin, moreover several data shown 
that FGF-21 expression is increased in adipose tissue of obese model mice (comparable to 
its expression in the liver) (Zhang, X. et al, 2008). 
FGF-21 also performs metabolic functions in the pancreas, where is able to preserve 
β-cell function and survival by activation of extracellular signal-regulated kinase ½ and 
Akt signaling pathways, and inhibiting glugacon secretion, that induce a reduction of 
glucolypotoxicity and apoptotic effect mediated by cytokine (Wente W. et al, 2006), these 
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actions could correlated with a reduction of glucose levels in the blood.  Moreover FGF-
21 acts in the liver, where is able to induces gluconeogenesis, (increasing glucose-6-
phosphate and phosphoenol-pyruvate carbokinase), it does not stimulate glycogenolisys. 
In a search for proteins that can modulate glucose metabolism, FGF-21 was found to 
increase glucose uptake into cultured 3T3-L1 mouse adipocytes and primary human 
adipocytes, through upregulation of glucose transporter (GLUT) 1 expression in an 
insulin- independent manner. Glucose uptake induced by FGF-21 is  insulin-independent, 
probably, because FGF-21 up-regulates GLUT-1 m-RNA, and because through its 
binding to β-Klotho–FGFR1 complex, FGF-21 stimulates glucose uptake in differentiated 
adipocytes via the induction of glucose transporter-1 (GLUT1)  whereas insulin acts 
through GLUT-4. FGF-21 needs to be express on cells for several hours, to produce a 
considerable response in glucose uptake, (FGF-21 effects are significantly diminished by 
the proteininhibitor cycloheximide), while insulin is known to work in a rapid manner, 
because  FGF-21 activity is mediate by gene expression, unlike insulin that acts in a direct 
way (Kharintonenkov A. et al, 2005). To better understand the FGF-21 functions on 
glucose metabolism directly, in some studies recombinant FGF-21 was subsequently 
administered to various diabetic and metabolic disease models, all of these studies 
demonstrated a dramatic effect of FGF-21 in normalizing plasma glucose levels and 
improving insulin sensitivity. Similar results were obtained in FGF-21 transgenic animals 
in which  levels of serum insulin were significantly decreased like at the same time 
glucose, cholesterol and hepatic TG levels, improved insulin sensitivity, and were 
resistant to diet-induced obesity. All these data can suggest a role of FGF-21 in metabolic 
diseases, such as diabetes.  In addition to the reduction of blood glucose levels, another 
pharmacological effect of FGF-21 is the lowering of blood content of cholesterol and 
triglyceride. FGF-21 in fact is able to induces, by increasing the carboxyl ester lipase, 
fatty acids oxidation in the liver. Studies on FGF-21 Knock Out animal rodent model 
animals showed impaired Ketogenesis, hepatosteatosis and alterations in the control of 
glucose metabolism (Cicione et al, 2012) suggesting the crucial role of FGF-21 for these 
metabolic events.  Some studies explain this action, suggesting that FGF-21 also induces 
the production of several pancreatic lipases, like pancreatic lipase, lipase-related protein 
and carboxyl ester lipase in the liver,  in addiction it is shown that administration of FGF-
21 to mice is able to stimulate the expression of some genes in adipose tissue (WAT and 
BAT both), mainly uncopling- protein 1 (UCP1), PPARγ  co-activator 1α (PGC1α), 
  
6 
 
hormone-sensitive lipase (HSL), adipose TG lipase (ATGL) and acetyl CoA carboxylase2 
(ACC2). Furthermore induction of these lipases can contribute to enhance the hepatic 
fatty-acids metabolism (Andrews MT. et al, 1998). Biochemical studies shown notable 
reductions of triglyceride and cholesterol in the liver and in the muscle of FGF-21-
treatedhigh-fat diet–induced obesity (DIO) mice, accompanied by reductions of plasma 
AST, ALT, and ALP levels. In adipose tissue sections it was observed reduced lipid 
accumulation in FGF-21-treated DIO mice. The increasing of fatty acids metabolism 
induced by FGF-21 in the liver and other tissues like muscle and adipose tissue, is related 
to reduction of TG plasma levels, and reverted hepatosteatosis. In fasting response, the 
nuclear co-activator PPARα is induced to stimulate ketogenesis, gluconeogenesis and 
fatty acids metabolism, all effects are mediates by the action of FGF-21. It is shown that 
FGF-21 also  regulates fasting promoting lipolysis in WAT from murine adipocytes and 
ketogenesis, and in liver in response to fasting directly induced by PPARα although this 
FGF21-induced lipolysis; these evidences demonstrate a role for the PPARα-FGF-21 
endocrine signaling pathway, in regulating several metabolic and behavioral aspects of 
the adaptive response to starvation (Kurosu and Kuro, 2009). The favorable effect on 
hepatic steatosis might be related also to the inhibition of the maturation of sterol 
regulatory element-binding protein-1c, a transcription nuclear factor that activates all 
genes required for lipogenesis. 
 It is shown that FGF-21 is also involved in the regulation of the body-weight and 
body fat mass. It is observed elevated blood concentrations of FGF-21 in obesity; some 
studies demonstrate a weight loss in diabetic no human primates, after chronic 
administration of FGF-21 (Kharitonenkov A, et al 2007), confirming that in  obesity there 
is a  FGF-21-resistant state; to accept this in FGF-21 overexpressing mice it is evident a 
reduced fat mass content and reduction of resistance to obesity (Ficher ML. et al, 2010). 
Moreover FGF-21 reduces physical activity and promotes torpor in mice to save energy 
by reducing physical activity and body temperature energy.  
Recently, many studies have investigated the pharmacological effects of FGF-21 in 
humans. Due to its involvement on the reduction of glucose levels in the blood, FGF-21 
can be considered such as diagnostic marker to identify diabetes mellitus II in humans. 
Several authors related increased plasma levels of FGF-21 with an alterated glucose 
metabolism; elevated circulating concentrations of FGF-21 have been observed in insulin 
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resistant diabetes (Type II diabetes), whereas FGF-21 plasma levels are decreased in 
autoimmune condition (Type I diabetes) (Xiao Y. et al 2011). As demonstrate in animal 
models, FGF-21 plays a role also in obesity in humans: increased FGF-21 serum levels 
have been found to be associated with obesity in both children and adults, indicating a 
connection between FGF-21 and body fat mass (Reinehr T et al 2012). It seems that FGF-
21 can have also a role in cardiologic and renal disease. In fact, it is recently reported   
that FGF-21 levels may be altered in coronary and renal diseases. In a clinic study, 
median plasma FGF21 levels were significantly higher in CHD patients than in control 
subjects. Moreover in CHD patients with diabetes or hypertension, or both FGF-21 levels 
were higher than those of patients without these comorbidities. In this study it is observed 
that plasma FGF-21 concentrations are positively related with TG, fasting blood glucose, 
apolipoproteinB100, insulin, and HOMA index of insulin resistance, but negatively with 
HDL and apolipoprotein A1. These evidences can suggest a positive relationship between 
FGF-21 and adverse lipid profile in CHD patients and a possible compensatory response 
or resistance to FGF-21 (Lin Z et al 2010). Others studies have been demonstrated that 
circulating FGF-21 levels are also associated with renal function and progressively 
increased from early- to end-stage renal disease (ESRD). It is observed FGF-21 serum 
levels to bew8–15 times higher in long-term dialysis patients compared with healthy 
subjects. FGF-21 mighty has a role in insulin resistance in ESRD patients. These data 
shown that FGF-21 is positively correlated with inflammatory markers such as 
interleukin-6, fibrinogen, high-sensitivity C-reactive protein and HOMA-IR and 
negatively with residual renal function in a group of 72 non-diabetic peritoneal dialysis 
patients. Increased FGF-21 plasma concentration in dialysis patients, could be due to 
impaired renal excretion combined with compensatory mechanisms to counteract 
metabolic stress and/or insulin resistance and FGF-21 resistance in peripheral tissues 
(Han SH et al 2010). 
Finally a recent study shown that FGF-21 expression may be induced during 
multiple intracellular stress signals, such as oxidative stress, amino acid deficiency and 
also unfolding protein response (UPR). In UPR FGF-21 is induced by ATF4 and its 
pathway (PERK/eIF2-α/ATF4), that is strongly expressed in UPR (Schaap et al 2013). 
Several studies highlight FGF-21 also like a marker of mitochondrial disease in different 
kind of disorders (Gavrilova R and   Horvath R 2013).  Mitochondrial dysfunction can 
result in central nervous system damage, especially in the brain stem and cerebellar 
  
8 
 
region. Increased plasma  FGF-21 levels  has been found in spinocerebellar atrophy 
(SCA)  patients (Su et al 2012); this can suggest a role of FGF-21 in central  nervous 
system, despite the expression and functions of FGF-21 in the brain are so far unknown. 
All these data underscore the multiplicity of physiological and pharmacological actions of 
FGF-21 in various tissues. All the effects of FGF-21 are mediated by the interaction with 
its receptors, which by forming a protein complex with the coactivator β-Klotho, can 
activate a series of downstream effects, including the induction of expression of certain 
proteins which in turn activate a series of responses to various environmental stimuli.  As 
largely demonstrate, one of the factors involved in mainly activity of FGF-21 is the 
transcriptional co- activator PGC-1α whose expression is strongly increased by FGF-21, 
in different tissues. 
 
 
FGF-21 induces PGC-1α 
 
FGF-21 can play its metabolism regulation functions by inducing the production of 
proteins able to activate a number of downstream pathways; in some cases FGF-21 cannot 
perform their functions without the involvement of other factors, such as PGC-1α.In 
several studies it is observed that administration induces, in mice liver, the expression of 
the transcriptional co-activator peroxisome proliferator-activated receptor c protein-1α, 
which interacts with several different DNA-binding proteins to regulate oxidative 
metabolism in response to several physiologic stimuli. In the liver, the induction of PGC-
1α can stimulates the transcription of genes involved in gluconeogenesis, fatty acid 
oxidation, and ketogenesis. Importantly, FGF-21 is unable to induce gluconeogenic gene 
expression in  transgenic mice lacking PGC-1α. Moreover, mice lacking FGF-21 cannot 
induce PGC-1α expression in response to a prolonged fast and have impaired 
gluconeogenesis and ketogenesis (Potthoff MJ et al 2009). Thus, others metabolic actions 
of FGF-21 are mediated in part through PGC-1α. In a recent study it is reported the ability 
of FGF-21 in the endogenous cold response. FGF-21 expression is also necessary for the 
cold-induced recruitment of brown-like adipocytes in WAT; in fact FGF-21 
administration can stimulate thermogenic gene response in both BAT and 
thermogenically competent WAT depots. This action is related with a massive induction 
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of PGC-1α protein, because it is required for the thermogenic effects (Ffolliott M. et al 
2012). Today FGF-21 is the only secreted protein known induced by cold that can 
increase, by inducing PGC-1α expression, the appearance of brown-like/brite adipocytes 
in WAT depots. In adipose tissue PGC-1α acts in concert with both AMPK and Sirtuin-1 
(SIRT-1) to regulate energy homeostasis in response to environmental and nutritional 
stimuli; available data shown that treatment with FGF-21 can increase AMPK and SIRT-
1 activities via LKB1 in human adipocytes. SIRT-1 activation is mediated by the 
alteration of NAD
+
 levels, resulting after FGF-21 treatment. The activation of these 
metabolic regulators results in enhancement of mitochondrial oxidative function, 
clarifying the FGF-21 beneficial effects on metabolism and correlation between FGF-21 
mediate PGC-1α effects (Chau et al 2010). Together these findings suggest the crucial 
role of PGC-1α in FGF-21 main functions, band assumes a correlation between the two 
molecules also in other districts. 
 
 
Peroxisome proliferator-activated receptor c co-activator protein-1α 
(PGC-1α) 
 
Transcriptional co-activators are proteins able to regulate gene expression without 
recognizing and binding specific DNA sequences, but identifying and binding proteins, 
transcriptional factors, that requiring co-activators or co-repressors to act.  PGC-1α was 
identified in a differentiated brown fat cell line, it belongs to a family of co-activators 
with PGC-1β and PGC-1 related co-activator (PRC), that have functions in mitochondrial 
physiology. PGC-1α and PGC-1β contain a conserved amino acids sequence, LXXL, 
which represents the domain able to interact with nuclear factors and host cell factor 1 
interacting motif (Lin et al 2003); PRC also contains an activation domain and an RNA-
binding domain, but the homology with both other members of the family is so limited.  
PGC-1α gene is located on chromosome 5 in mice (chromosome 4 in human); it is a 797 
amino acids long protein (798 aa in human). PGC-1α powerfully regulates oxidative and 
mitochondrial metabolism in a number of tissues, induces mitochondrial biogenesis, it is 
able to interact directly with the basal transcriptional machinery, and the mediator 
complex, to activate the transcription. The co-activator  can induce gene expression also 
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recruiting chromatin-modifying enzymes, such as the histone acetylase p300, to open the 
chromatin for the activity of the transcription complex. In addition, PGC-1α can regulate 
gene expression by coordinating post-transcriptional events, because interacts with the 
splicing machinery. Structurally,  the PGC-1α protein has 200 amino acids at  N-terminus  
in which resides  the transcriptional activation domain, that interacts with SRC-1, CBP/p-
300, steroid receptor co-activator 1, c-AMP and several histone acetyl-tranferase 
complexes. In the central region (aa 200-400) there is the repression domain, that binds 
some transcription factors.   The C-terminal domain contains a region which recognizes 
and binds proteins involved in RNA processing, like hnRNP proteins (Krecic and 
Swanson, 1999) (Fig.3). Specific post-translational modifications such as phosphorilation, 
acetylation, and methylation on specific amino acids residues modulate the activity of 
PGC-1α as well as interactions with other proteins. Sirtuin-1 (SIRT-1) is an important 
regulator of PGC-1α activity, it acts through lysine de-acetylation; moreover SIRT-1 can 
increase the rate of transcription maintaining the de-acetylated active form of the protein 
(Gerhart-Hines et al 2007).   
 
 
 
 
 
 
 
 
 
 
PGC-1α is expressed in tissues which have high energy demand, like heart, skeletal 
muscle, liver, brain, kidney, brown adipose tissue (BAT) (fig.4).  In muscle and BAT,  
 
Fig. 3- Architecture of the PGC-1α transcriptional co-activator. PGC-1α contains 
several functional domains that correlate with the interactions with different 
proteins and complexes. 
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PGC-1α induces nuclear and mitochondrial genes to stimulate mitochondrial 
biogenesis, this effect is accompanied with the co-activation of nuclear respiratory factors 
1 and 2 (NRF1, NRF2) and the estrogen-related receptor a (ERR-a) (Mootha et al 2004); 
NRF1 and NRF2 enhance the expression of mitochondrial transcription factor A (mt-
TFA) that translocate in the mitochondrial matrix, and stimulate mt-DNA replication and 
gene transcription. Moreover NRF1 and NRF2 induce expression of members of the 
electron chain complex (cytochrome C, ATP synthase, and CoXIV) (Scarpulla, 2002). 
PGC-1α exerts its functions also in  Central Nervous System (CNS) which is  widely 
known that  is the most vulnerable tissue to oxidative stress. It is shown that an impaired 
PGC-1α expression in brain in concert with mitochondrial dysfunctions, can contribute to 
neurodegeneration in most susceptibles neural cells (Weydt et al 2006) so,  PGC-1α  has  
a notable task in normal brain functions and a pivotal role in   the oxidative stress 
response, because it regulates the expression of important factors against ROS, such as 
copper/zinc SOD1, manganese SOD1, and glutathione peroxidase 1 (St Pierre et al 2006). 
Some evidences indicate that in mice, PGC-1α deficiency can cause behavioral changes 
like anxiety and hyperactivity as well as hind limb clasping. These changes can be 
associated with spongiform-like vacuolization primarily in the striatum associated with 
Fig. 4- Representation of expression and functions of PGC-1α in 
different tissues. 
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gliosis and leads to reduced expression of several brain-specific genes that are all 
associated with normal brain functions. Some data suggest also an important role of   
PGC-1α in response to neurotoxins in neuronal maintenance in Substantia Nigra (SN) and 
Hippocampus (CA1) in neurons, that are more susceptible to oxidative stress and 
neurodegeneration (Lin et al. 2004). PGC-1α also seems to be involved in the control of 
neurite growth and neuronal synaptic function (Cowell et al. 2009). Some studies 
demonstrate a role of PGC-1α in the onset and progression of neurodegenerative diseases. 
In postmortem brain samples of patients with Hungtington’s Disease (HD), it was found a 
decreased level of PGC-1α mRNA (Cui et al. 2006;Weydt et al. 2006). A mutant form of 
the Huntington protein, which leads to mitochondrial dysfunction and neurodegeneration, 
represses PGC-1α. Loss of PGC-1α in HD mice aggravated neurodegeneration and its 
over-expression can rescue cells from the deleterious effect of HD (Cui et al. 2006). 
Moreover, PGC-1α KO mice show HD like phenotype and neuronal lesions suggesting 
that PGC-1α is crucial for maintenance of striatal function. Additionally, PGC-1α SNPs 
are associated with the age of onset of HD. Polymorphisms of PGC-1α  are also 
associated with the onset of Alzheimer’s Disease (AD) (Qin et al. 2009). Furthermore  in 
a Parkinson’s Disease (PD) mouse model with deficiency of PGC-1α, degeneration of 
dopaminergic neurons the SN was increased and associated with oxidative damage (St-
Pierre et al. 2006;Bender et al. 2006). 
There is a significant evidence that mitochondrial dysfunction and oxidative stress 
are a causative or at least ancillary factor in the pathogenesis of major neurodegenerative 
diseases. The  loss of regulation of inflammatory markers  induced by oxidative stress 
blocks the antioxidant systems, and causes inability to synthesize new proteins, disorders 
of the proteasome, accumulation of misfolded proteins and, the conformational change in 
key receptors involved in metabolism and cell signaling (Sevcsik et al. 2011). All these 
factors, accumulated slowly over time contribute to the establishment of 
neurodegenerative disorders that may manifest as abnormalities that cause the state of 
chronic oxidative (Halliwell 2006). Parkinson’s Disease, Alzheimer’s disease, 
Huntington’s disease and amyotrophic lateral sclerosis (ALS) are examples of 
neurodegenerative diseases in which there is an important involvement of oxidative 
stress, as well as in cases of stroke, trauma, and seizures (Beal et al. 2000; Ienco et al. 
2011); moreover, oxidative stress is a common pathogenic mechanism underlying many 
major psychiatric disorders (Wang et al. 2009). It is shown that activators of PGC-1α such 
  
13 
 
as others molecules that can induce it expression, like resveratrol (RSV), have a 
neuroprotective effect in acute and chronic brain injury as well as in neurodegenerative 
diseases suggesting also a role for PGC-1α in modulating the outcome of the disease (Sun 
et al. 2010). Due to its action on regulation of cell metabolism, mitochondrial biogenesis, 
and regulation of antioxidant enzymes, a number of evidences demonstrate an important 
involvement of PGC-1α in neurodegenerative diseases. Studies shown role for PGC-1α in 
modulating the outcome of the disease, brain injury, and indicate PGC-1α and SIRT-1 
like potential targets to treat neurodegenerative diseases such as Parkinson’s Disease, and 
more recently, studies shown that PGC-1α can also have a neuroprotective effect in 
dopaminergic neurons in animal model of Parkinson’s disease.  
 
Parkinson’s Disease and neuroprotective effects of PGC-1α in 
dopaminergic neurons 
 
Parkinson's disease represents one of the strongest cases based in part on post-
mortem studies that have shown mitochondrial impairment (e.g. reduced complex I 
activity) and oxidative damage in idiopathic PD brains. Clinically it is manifested by the 
tetrad of motor manifestations of tremor, rigidity, slowness of voluntary movements, and 
poor balance (Fahn, 2003). PD seems to be   essentially as a sporadic condition, that is, in 
absence of any evidence of genetic linkage, but, in a handful of cases, can derive from a 
variety of genetic defects, such as mutations in α-synuclein (Polymeropoulos et al. 1997), 
parkin, DJ1 (Bonifati et al. 2003), PINK1 (Valente et al. 2004), and LRRK2 (Zimprich et 
al. 2004) it is inherited (Dauer and Przedborski 2003). These different forms have not 
distinguishable symptomatology, and present the same biochemical alterations: a drastic 
deficiency in brain dopamine. The reason for this reduction in brain dopamine is because 
all of the ascending dopaminergic pathways in the CNS degenerate, albeit to variable 
degrees. For instance, among these pathways, the nigrostriatal pathway-which is 
composed of dopaminergic neurons residing in the ventral midbrain nucleus, the SN, and 
which projects upward to the striatum, is consistently the most severely affected. It is 
remarkably, however, that PD neurodegeneration not involves only the dopaminergic 
systems, but the widespread neuronal loss can be detected in other catecholaminergic and 
noncatecholaminergic nuclei in fact motor symptomatology is due to  neurodegeneration 
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in the dopaminergic systems, whereas  others manifestations of PD, such as pain, 
cognitive impairments, and constipation, are more likely linked to neurodegeneration in 
different circuits. Post mortem samples of PD patients present the “Lewy bodies”, that are  
intraneuronalproteinaceus  inclusions,  of insoluble proteins, overall α-synuclein found 
within many of the spared neurons in nearly all affected brain areas (Shults, 2006) and 
gliosis (Przedborski, 2007). Several studies showed that the initial degeneration of 
dopaminergic neurons in PD is increased by production of ROS originated in all cell 
compartments. The elevated ratio of ROS can damage all cell systems and molecules. The 
primary source of production of ROS is precisely the metabolism of dopamine, 
neurotransmitter that resides in synaptic vesicles, but that can diffuses into the cytosol 
when it is produced in excessive amounts, because its metabolism is by its oxidation 
performed by the enzymes  Monoamino Oxidase  (MAO), which mainly produces H2O2 
and dihydroxyphenylacetic acid (DOPAC) (non-enzymatical and spontaneous auto-
oxidation of dopamine produces O2- and reactive quinones). Enzymatic oxidation of 
dopamine to H2O2 causes also increased formation of oxidized glutathione, suggesting the 
occurrence of oxidative stress and impairment of a major antioxidant system; H2O2 in 
dopaminergic neurons interact by SOD with nitric oxide radicals (NO) to consequently 
generate peroxynitrite, moreover the abundance of metals in these neurons cause the 
production of radical OH.  It is known that in PD, another cause of ROS and oxidative 
stress resides in mitochondrial alterations. Furthermore, NO accumulation can form 
adducts with mitochondrial enzymes and dysregulate mitochondrial function (Ebadi and 
Sharma, 2003; Yamamoto et al., 2007). Keeney at al observed a central role of 
mitochondrial dysfunction in PD, due to deficits in the subunits and activity of 
mitochondrial complex I (NADH ubiquinone Oxidoreductase) of the electron transport 
chain and a decrease in the function of Complex III, found in blood platelets, 
lymphocytes and SNc  of PD patients. Moreover several data confirm the predominant 
role of mitochondrial disfunction on PD. It was shown that SNc dopaminergic neurons 
have high amount of mt-DNA deletions in PD patients, if compared with other neuronal 
populations in brain- and age-matched controls (Bender et al. 2006). A related study 
identified that nigral neurons from PD patients contain high levels of clonally expanded 
somatic mt-DNA deletions leading to mitochondrial dysfunction (Kraytsberg et al. 2006). 
Mitochondrial DNA is particularly susceptible to oxidative damage. The lack of the 
physical protection histones,   vicinity with ROS source (electron transport chain) and the 
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absence of inefficient repair mitochondrial machinery can explain this susceptibility.  
Recent studies suggest that also Endoplasmatic Reticulum stress by accumulation of 
unfolded and/or misfolded proteins contribute to PD (Wang and Takahashi 2007). Other 
evidence demonstrate that  inflammation can also contribute to ROS production and has 
been implicated in the pathogenesis of PD; in fact, activation of microglia in response to 
injury is associated with an up-regulation of inducible nitric oxide synthase (NOS) 
resulting in increased production of NO (Drechsel and Patel 2008). Finally it is also 
observed a contribute to PD pathogenesis by Endoplasmatic Reticulum stress by 
accumulation of unfolded and/or misfolded proteins (Wang and Takahashi 2007). All 
these evidence focused the importance of mitochondrial functions in the pathogenesis of 
neurodegenerative diseases of PD. As largely shown one of the crucial molecules for the 
mitochondrial activity is PGC-1α,  it, in fact,  plays a pivotal  role in the expression of 
genes responsible for the detoxification of ROS, including copper/zinc SOD1, manganese 
SOD2, and glutathione peroxidase 1 (St-Pierre et al. 2006). Interestingly, SIRT-1, 
activator of PGC-1α, plays a similar role in oxidative stress function in combination with 
Fox-O transcription factors (Brunet et al. 2004). For this reason, PGC-1α plays an 
important role in normal brain function and a major role in the oxidative stress response. 
These evidences have suggested a role of PGC-1α on protection against oxidative stress 
in neurodegenerative disease. Mudò et al, have recently studied and demonstrate that in 
transgenic overexpressing mouse model PGC-1α is able to confer neuroprotection to the 
dopaminergic neurons in SN, on MPTP model of Parkinson’s disease. In fact it was 
observed, in the SN of overexpressing PGC-1α mice the number of neurons, on MPTP 
treated mice were essentially unchanged to controls and wild type ones. This study 
showed the PGC-1α transgenic mice were significantly more resistant to MPTP-induced 
neurotoxicity than the wild-type mice as reflected also by smaller reduction of dopamine 
and DOPAC. In addition, the increase of dopamine/DOPAC ratio was lower in the PGC-
1α transgenic mice as compared to controls. Moreover in overexpressing PGC-1α model 
it was evident an increased rate of respiratory control rate in mitochondria as compared to 
organelles from wild-type mice, indicating  that the neuronal capacity for ATP production 
is higher in these mice compared to wild-type animals. Moreover the authors observed 
that resveratrol (RSV) treatment in murine dopaminergic cell line (SN4741), is able to 
increase the levels of SIRT-1 and activated PGC-1α, by reducing acetylation of the 
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protein. RSV increases the levels of PGC-1α in the dopaminergic cells by affecting gene 
expression. 
These data, together, underscore the importance of PGC-1α signaling in 
neuroprotection of dopaminergic neurons, and adds to previous studies on the role of 
PGC-1α in models of neuronal excitotoxicity and cell stress (St-Pierre et al. 2006; Lu et 
al. 2010).It is largely known that PGC-1α expression   is enhanced in several metabolic 
tissues by growth factors as FGF-21, knowledge on the involvement of FGF-21 in 
mitochondrial disorders associated with important antioxidant activity of PGC-1a we 
suggest a possible correlation between these molecules at the level of the central nervous 
system. 
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Aims 
 
FGF-21 is a growth factor that plays a role in balance energy excerting hormone-
like effects functions on metabolism. It has metabolic actions and is involved in a 
protection mechanism against oxidative stress in different tissues, such as liver, muscle 
and adipose tissue. Moreover FGF-21 is able to induce PGC-1α expression, to exert its 
functions. PGC-1α is a transcriptional co-activator with important neuroprotective effects 
in dopaminergic neurons. On the basis of these evidences the aim of the present study was 
to investigate if FGF-21 induces PGC-1α in human dopaminergic neurons. To this end we 
treated human dopaminergic neurons cell line with FGF-21, we studied its effect on   
PGC-1α gene expression, protein activity, including its mitochondrial effects. Another 
aim of this work was to explore the possible expression and functions of FGF-21 in the 
brain; we performed these studies, in animal model of oxidative stress induced with 
kainic acid treatment.  
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Materials and Methods 
 
Cell culture 
 
We performed our in vitro experiments using human mesencephalon neuronal 
precursor cells (MESC2.10 cells), cultured in in poly-Dlysin (Sigma, St Louis, MO, USA) 
coated flasks (75cm2) in Dulbeccos modified Eagle medium (DMEM)/F12 medium 
(Gibco, Invitrogen, Calrsbad, CA, USA) supplemented with B27 (Gibco) and 
Penicillin/streptomycin and human basic FGF 20ng/ml (Peprotech, Rocky Hill, NJ, 
USA).  Cultivating cells for 6 days on poly-Dlysine/ laminin (Sigma) coated wells at a 
density of 30000 cells /cm2 in a medium containing 1μg/ml tetracyclin (Sigma), we were 
able to  induce the differentiation into dopaminergic neurons (Lotharius et al., 2002; Di 
Liberto et al., 2012), the medium was changed every second day. To verify the state of 
differentiation we monitored the expression of markers for dopaminergic neurons such as 
tyrosine hydroxylase and dopamine transporter. Microglial and astrocyte cells were 
prepared from newborn of rodent brains, and cultured fetal calf serum in DMEM  for two 
weeks (Lindholm et al., 1992; Mäkelä et al., 2010).  The human hepatocyte cell line Huh7 
was used as a positive control for FGF21 expression (Do et al., 2012). 
 
 
Animals 
 
In vivo experiments were performed using three months old female Wistar rats. 
Animals were kept under environmentally controlled condition, ambient temperature     
24 °C, humidity 40 %, and 12 h light/dark cycle with food and water ad libitum. 
Procedures involving animals and their care were conducted in conformity with 
institutional guidelines that are in compliance with national (D. L. n. 116, G. U., suppl. 
40, 18 February 1992) and international laws and policies (EEC Council Directive 
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86/609, OJ L 358, 1, 1 December 12, 1987).  Rats were injected with KA (0.35 μg per 
side) in lateral ventricle, (ICV) and killed at different time-points after 24, 48 and 72 
hours; controls  received same treatment injection with saline. Animals were killed under 
deep anesthesia followed by cervical dislocation. Collected brains were immediately 
frozen in isopentane and stored at -80°C. 
 
Immunoblotting 
 
We treated the MESC2.10 differentiate cells with 50 ng/ml of FGF-21 (R&D 
Systems, Minneapolis, MN, USA). After 24h cell samples were lysed with RIPA buffer 
containing 150mM NaCl, 1% Triton-X 100, 0,5% sodium deoxycholate, 50mM, pH 8, 
and 0, 1% sodium dodecyl sulfate (SDS).  Using SDS-PAGE, 30–30 µg of protein was 
separated, transferred to nitrocellulose membranes (Hybond-C-Extra, Amersham 
Biosciences, Buckinghamshire, UK), blocked for 1 hour  at room temperature in TBST 
and 5% skim milk, and incubated overnight at 4°C with primary antibodies. We used anti-
α-PBEF/NAMPT (1:1000; Abcam, Cambridge, UK), anti-SOD2 (1:5000; AbFrontier, 
Seoul, Korea), anti-Trx2 (1:1000; AbFrontier), anti-PGC-1α (1:5000; Calbiochem, San 
Diego, CA, USA), anti-COX IV (1:2000; Abcam), anti-mtTFA (1:1000; Abcam), anti-
FGF21 (1:3000; Novus Biologicals, Littleton, CO, USA) and anti-β-actin (1:5000; 
Sigma). The membranes were washed in TBS 5%, Tween 20 buffer and incubate for 1h at 
room temperature, with peroxidase-conjugated secondary antibodies: (1:2500; Jackson 
Immuno Research, West Grove, PA, USA) were. Super Signal West Pico 
chemiluminescent substrate (Thermo, Waltham, MA, USA) was used for visualization of 
the bands, and ImageJ software for their quantification (http://rsb.info.nih.gov/ij/). 
Different brain regions of adult mouse were dissected under stereomicroscopy and 
frozen in cooled isopentane.  Brain tissue pieces were homogenized in cold buffer 
containing 50 mMTrisHCl pH 7.5, 100 mMNaCl, 1 mM DTT, 5% NP-40, 10 µg/ml 
aprotinin, 10 µg/ml leupeptin, 0.1 mMphenylmethylsulfonyl fluoride, 100 µM sodium 
orthovanadate (Na3VO4) and 1 mM EDTA (Sigma-Aldrich, St. Louis, MO, USA). The 
homogenate was left on ice for 30 min and centrifuged at 10,000 × g for 15 min at 4°C to 
yield supernatant fractions that were stored at -80°C until use. To obtain enough material, 
the two SN were pooled. 30–40 μg of protein was subjected to immunoblotting as above 
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using primary antibodies anti-FGF21 (1:3000) and β-actin as control. The membrane was 
processed as above using secondary antibodies and visualization of bands was made by 
enhanced chemiluminescence. 
 
 
Immunohistochemestry 
 
 To perform Immunohistochemestry experiments brains were taken from adult rats 
and  mounted into Tissue-Tek (Sakura Finetek, Netherlands) and frozen on dry ice 14μm 
thick  coronal sections were prepared  with a cryostat (Micron, HM 500 M, Walldorf, 
Germany)  as described (Putkonen et al., 2011; Koivuniemi et al., 2013).  Sections were 
gradually brought to room temperature  and dried, than fixed in Paraphormaldeyde 4% 
pH 7.4 for 15 minutes at room temperature, after a pre-incubation in blocking solution  
for 30 minutes (phosphate-buffered saline ⁄ 5% bovine serum albumin ⁄ 0.1% Triton-X-
100) at 4°C, sections were incubate  overnight at 4°C in humid chamber with primary 
antibodies (anti FGF-21 Novus Biologicals NBP1-59291 diluition 1:2000; anti TH 
Covance MMS-503P diluition 1:1000; anti-GFAP Chemicon MAB360 diluition 1:500; 
anti CD11 BD pharm 550299 diluition 1:50; anti CNP-ase Sigma C5922 diluition 1:500).  
Incubation with primary antibodies was followed by secondary antibodies Alexa 
488 or 594-conjugates. The nuclei were counterstained with bisbenzimide⁄ Hoechst 
(Sigma33258). 
 Sections were analyzed at r.t. with a confocalmicroscope (LSM 510 Meta; Carl 
Zeiss, Inc. in Minerva Foundation Insitute, Biomedicum, Helsinki) using ISM aim 
software and a magnification 40X. 
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Immunoprecipitation 
 
To made immunoprecipitation experiments we used lysates from human 
dopaminergic cells treated with 50ng/ml FGF21 for 24 h alone or together with 10mM 
nicotinamide (Acros organics, Geel, Belgium). PGC-1α antibody (Calbiochem) at the 
dose of 1,5 was added to 500μg of cell lysates overnight at +4°C under constant rotation. 
50μl of Protein G-agarose (Roche, Basel, Switzerland) was then added to the samples and 
incubated for 6 hours. After the incubation samples were recovered by centrifugation., 
beads were washed three times with RIPA buffer and lysates were run on 8% SDS-
PAGE, followed by transfer and using either anti-PGC-1α antibodies (1:1,000; Cell 
Signaling) or anti-acetylated-lysine antibodies (1:1,000; Cell Signaling). The intensity of 
the bands reveals the degree of acetylation of PGC-1a under different conditions as 
described above using first anti-acetylated lysine antibodies and then anti-PGC-1α 
antibodies. The quantifications of the bands were done using ImageJ software. The degree 
of acetylation of PGC-1α is an index for the activity of this protein in the cell (Rodgers et 
al, 2005; Mudò et al., 2012). 
 
 
Luciferase Assay 
 
To analyze gene expression levels of PGC-1α in dopaminergic neurons we made a 
luciferase assay. The neuronal precursors were transfected with 0,5μg of the PGC-1α–
luciferase reporter constructs or the control pGL3 promoter constructs together with 
0,025μg RenillapRL-TK plasmid using Fugene (Promega, Madison, WI, USA). Cells 
were incubated for 2 days in the differentiation medium and 50ng/ml FGF21 was added 
for an additional 24h. To control for transfection efficiency, 0.02 µg Renilla luciferase 
pRL-TK was used. Cells were harvested after 48 h using Passive Lysis Buffer, and the 
Renilla and the firefly luciferase activities were measured using a luminometer (Promega, 
Biofellows, Helsinki, Finland) (Kairisalo et al. 2009). Results are shown as fold increase 
in luciferase normalized to Renilla activity. 
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NAD+/NADH levels 
 
To estimate levels NAD+ we used the NAD+/NADH assay kit (Abcam) according 
to manufacturer’s protocol. The absorbance was measured at 450nm was using Multiscan 
MS Version 3.0 spectrophotometer.  
 
Real-time analyses of mitochondrial respiratory capacity in human 
dopaminergic neurons 
 
Differentiated for 5 days cells, were treated with 50ng/ml FGF2. After a 24h-
stimulation, cells were plated on Seahorse 96well plate (Seahorse Bioscience, Boston, 
MA USA). Medium was changed to HCO3-free DMEM (Sigma) containing 10mM 
pyruvate, 1mM l-glutamine and 10mM glucose 1h prior to analyses and keeping cells at 
+37°C without CO2. Relative oxygen consumption in dopaminergic neurons was 
determined in real-time using the Seahorse XFe96 analyzer (Seahorse Bioscience) by 
determining oxygen consumption as response to the addition of various chemicals. Three 
min cycles were run for every measurement and the following compounds were 
subsequently added using the Mitostress kit (Seahorse): 1μM Oligomycin (ATP synthase 
inhibitor), 0,8μM Carbonyl cyanide 4- (trifluoromethoxy) phenylhydrazone (FCCP) 
(mitochondrial uncoupler), 1μM Rotenone (complex I inhibitor of the respiratory chain) 
and Antimycin A (complex III inhibitor). 
 
 
Mitochondrial DNA copy number 
 
We isolated DNA from human dopaminergic neurons using QIAamp DNA Mini 
Kit (QIAGEN, Hilden, Germany) according to manufacturer’s protocol. To measure 
relative mitochondrial DNA (mtDNA) copy number we used  quantitative PCR and 
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compared the ratio of mtDNA to nuclear DNA and the method described previously 
(Xieetal., 2013). In brief, the ND1gene was used for quantifying mt-DNA and human 
globulin (HGB) gene for nuclear DNA. The primer sequences used were: forward primer 
ND1-F: 5´-CCT AAA ACC CGC CAC ATC T-3´, reverse primer ND1-R: 5´-GAG CGA 
TGG TGA GAG CTA AGG T-3´; forward primer HGB-F: 5´-GTG CAC CTG ACT CCT 
GAG GAG A-3´, and reverse primer HGB-R: 5´-CCT TGA TAC CAA CCT GCC CAG-
3´. The PCR reaction mixture contained 5ng DNA and 200nmol/l of forward and reverse 
primers in 1X SYBR Green Mastermix (Roche). The reaction was carried out at 95°C for 
10min followed by at 95°C for 15s and 60°C for 1min using 40 cycles. Each sample was 
run in triplicates on a 96- well plate and water was used as negative control. Quantitative-
PCR amplification was performed using Light Cycler 480 II instrument (Roche) as 
described (Do et al., 2012; Hyrskyluoto et al., 2013). The ratio of mt-DNA to nuclear 
DNA reflects the concentration of mtDNA per dopaminergic cell. 
 
 
Electron microscopy and mitochondrial density analysis 
 
Human dopaminergic neurons stimulated with 50ng/ml FGF21 for 24h were fixed 
with 2,5% glutaraldehyde in PBS for 1h at room temperature and washed two times with 
H2O for 1hour. Postfixation was done using 1% osmiumtetroxide. The embedding and 
sectioning procedures were done essentially as described before (Korhonen et al., 2008). 
The sections were stained with lead citrate and uranyl acetate and viewed using a Jeol 
JEM-1400 transmission electron microscope (Jeol Ltd., Tokyo, Japan) equipped with 
GatanOrius SC 1000B bottom mounted CCD-camera (Gatan Inc., USA). Mitochondria 
identified in the EM pictures of the cells were marked manually and the relative surface 
area was calculated using the ImageJ software. Results were pooled from different 
sections of control and FGF21-treated cells and the density of mitochondria was 
compared. 
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Animal experiments 
 
To activate microglial cells rats were injected with kainic acid (Sigma, Helsinki, 
Finland) into the lateral ventricle (0.35 μg/μl) in a volume of 0.5 μl per side as described 
previously (Sokka et al., 2007; Putkonen et al., 2011). Animals were kept for different 
times: 24 hours, 48 hours and 72 hours and decapitated in deep anesthesia, and brains 
were rapidly dissected, frozen in isopentane, cooled in liquid nitrogen and stored at −70 
°C until being processed for immunohistochemistry as described above. 
Experiments were approved by the ethical committee and carried out in accordance 
with the European Communities Council Directive (86/609/EEC). Every attempt was 
made to reduce the number and to minimize pain and suffering of animals. 
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Results 
 
FGF-21 is able to increase levels and deacetylation of PGC-1α in 
cultured human dopaminergic neurons 
 
The first aim of the present work was to analyze the effects of FGF-21 on PCG-1α 
expression and activity in human dopaminergic neurons.  To carry out our research we 
cultivated midbrain progenitor (MESC2.10) cells from human embryonic brain that were 
further differentiated into dopaminergic neurons in culture (Lotharius et al., 2002).  We 
treated the cell line with 50ng/ml FGF-21 for 24hours. After 24 hours we used cell lysate 
to perform immunoblotting experiments employing an anti PGC-1α antibody. We 
observed that the FGF-21 treatment led to an  increase in PGC-1α protein as shown in the 
Figure 5. To clarify whether this involved increased gene expression we used the      
PGC-1α-promoter linked to a luciferase reporter gene, transfecting our neuronal precursor 
cell line with an appropriate plasmid construct. Our results indicate that the gene activity 
of the PGC-1α promoter was increased by FGF-21 treatment with no changes in the 
activity of the pGL3 basic-promoter used as control (Fig. 6). 
 
 
 
 
 
Fig. 5-  FGF-21 increases PGC-1α levels in dopaminergic neurons.- Immunoblots. β-
actin was used as a control. The levels of PGC-1α were increased by FGF21 as compared 
to control. Left, typical immunoblot. Right, quantification done using ImageJ software. 
Values are means± SD, n=4, ***p<0.001 for FGF21 vs controls. 
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We also observed an increase in PGC-1α mRNA levels in FGF21-treated 
dopaminergic neurons using quantitative PCR (data not shown). These data indicate that 
FGF-21 treatment is involved in the  increase the  PGC-1α of protein levels, and genic 
expression.  The activation of functions of PGC-1α depends by its post-translational 
modifications, such as the removal of acetyl groups in specific amino acidic residues. It is 
know that the de-acetylation of the lysine can activate the gene co-activator function of 
PGC-1α, in fact this kind of modification facilitates the binding with other proteins that 
recognize and bind DNA. 
Fig.6: FGF-21 enhances the activity of  
PGC-1α gene promoter- Gene promoter 
assays. Cells were transfected with the pGL3 
basic plasmid and the PGC-1α promoter 
plasmids linked to a luciferase reporter gene. 
Cells were stimulated with FGF21 for 24h 
and the luciferase activity was measured and 
corrected for that of Renilla as described as 
described in Methods. FGF21 enhanced 
PGC-1α gene activity but not that of the 
control pGL3 promoter. Values are means± 
SD, n=4, *p<0.05 for FGF21 vs controls. 
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To study whether FGF-21 could activate PGC-1α protein we performed 
immunoprecipitation to evaluate the degree of acetylation of specific lysine residues (that 
need to activate the protein). Experiments followed by immunoblotting using anti-PGC-
1α and anti-acetylated lysine antibodies.  
 In the treated cell samples with FGF-21 was evident a reduction of the relative 
degree of acetylation of PGC-1α as compared to control (Fig.7). Collectively these data 
indicate that FGF-21 is able to increase the level of protein in the cell,   and can increase 
also the activation status of PGC-1α in the human dopaminergic neurons. 
 
 
 
 
 
 
 
 
FGF-21 increases Nampt and NAD+ levels and SIRT-1 in the 
dopaminergic neurons 
 
 SIRT-1 is a deacetylase, it shifts acetyl groups from PCG-1α and consequently can 
active it. This reason led us to investigate if FGF-21 could influence also the SIRT-1 
activity. Results of immunoblot experiments with an anti-SIRT-1 antibody, shown that 
Fig.7- FGF-21 decreases the deacetylation degree of PGC-1α in dopaminergic 
neurons-  Immunoprecipitation experiments. PGC-1α was immunoprecipitated from 
control and FGF21-treated cells followed by immunoblotting as described in Methods. 
The degree of acetylation of PGC-1α was analyzed using the anti-acetylated lysine 
antibody. Total amount of PGC-1α in the immunoprecipitate was analyzed using anti-
PGC-1α antibodies. Values are means± SD, n=4, *p<0.05 for FGF21 vs Controls. 
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stimulation of cells for 24 hours with 50ng/ml FGF-21 increased SIRT-1 levels (Fig. 8).  
FGF-21 treatment, after 24 hours is also able to increase NAD+ levels in human 
dopaminergic neurons (Fig. 9).  NAD
+ 
that are important in redox reactions and ATP 
production in the cell and is the important co-factor to active SIRT-1. We measure NAD+ 
levels using the NAD+/NADH assay. 
 
 
 
 
 
 
 
Fig 8- FGF-21 increases SIRT1 levels in dopaminergic neurons- Immunoblots. β-
actin was used as a control. The levels of SIRT1 were increased by FGF21. Left, 
immunoblots. Right, quantifications using ImageJ. Values are means± SD, n=4, 
***p<0.001 and *p< 0.05 for FGF21-treated vs Controls. 
 
 
Fig. 9- FGF-21 increases 
NAD/NADH levels in 
dopaminergic neurons- The 
ratio of NAD+ to NADH in the 
dopaminergic neurons was 
measured as described in 
Methods. FGF21 increased 
NAD+ levels in the neurons. 
Values are means± SD, n=4, *p< 
0.05for FGF21 vs Controls. 
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We also investigate the Nampt levels and we found it increased. Nampt is the 
enzyme that catalyzes the first step of NAD
+ 
biosynthesis, in fact it is the rate-limiting 
enzyme of NAD
+  
production. These data shown that FGF-21 increasing Nampt and 
NAD
+
 levels is able to active SIRT-1 a consequently PGC-1α in human dopaminergic 
neurons (fig. 8-9-10). 
To confirm these data we also incubate the cells, previously treated with FGF-21, 
with the SIRT-1 inhibitor nicotine amide (NAM). NAM induces the disactivation of 
PGC-1α because, blocking the activity of SIRT-1, increases the degree of lysine 
acetylated of PGC-1α. In our experiments NAM is able to counteract the FGF-21 action 
on PGC-1α in the human dopaminergic neurons (Fig. 12). Together these results indicate 
that FGF-21 acts on Nampt/NAD+/SIRT-1 pathway in the human dopaminergic neurons, 
with effect on the PGC-1α activation.  
 
 
 
 
 
 
 
 
 
Fig 10- FGF-21 increases Nampt levels in dopaminergic neurons- Immunoblots. β-
actin was used as a control. The levels of  Nampt were increased by FGF21. Left, 
immunoblots.Right, quantifications using ImageJ. Values are means± SD, n=4, 
***p<0.001 and *p< 0.05 for FGF21-treated vs Controls. 
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FGF21 increases mitochondrial antioxidants in human dopaminergic 
neurons 
 
We have previously showed that the levels of the mitochondrial antioxidants, SOD2 
and Trx2 were increased in the SN of PGC-1a transgenic mice compared with wild-type 
animals. Likewise, the mitochondrial enzyme COXIV was also elevated in the transgenic 
mice compared to controls (Mudò et al 2012). The increase in protein levels in the PGC-
1α transgenic mice was accompanied by an enhanced gene expression, as shown for 
SOD2 and COX IV, this suggest that overexpression of PGC-1α leads to changes in gene 
expression for a particular set of proteins in the SN with a protective function in cell 
Fig. 11: The SIRT1 inhibitor NAM increases the   
acetylation degree of PGC-1α-Immunoprecipitation 
experiments. Cells were stimulated with FGF21 for 24h in 
the absence or presence of 20 μM NAM that is an inhibitor 
of SIRT1. The degree of acetylation of PGC-1α was analyzed 
as above. Note an increase in acetylated PGC-1α due to 
SIRT1 inhibition by NAM. Values are means± SD, n=e, 
*p<0.05 for FGF21vs Controls. 
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stress. So here we investigate whether these antioxidants were also increased in human 
dopaminergic neurons after FGF-21treatments. Data prove that treatment with FGF-21 
strongly upregulates both SOD2 and Trx2 (Fig. 12). This suggest that the fibroblast 
growth factor-21 can contribute to neuroprotection against oxidative stress in the 
dopaminergic  neurons, and its action is mediate by the activation of PGC-1α, that 
induces an  increase of two important antioxidant mitochondrial enzymes antioxidants. 
 
 
 
 
 
 
 
 
 
 
Fig. 12-  FGF-21 increases 
mitochondrial antioxidant enzymes 
levels in dopaminergic neurons- (A) 
Immunoblots. β-actin was used as a 
control. FGF-21 increased the levels Sod2 
and Trx2 that are antioxidants localized to 
mitochondria. (B-C) Quantification. Sod2 
(B) and Trx2 (C) increased in 
FGF21treated neurons. Values are means 
±SD, n=4, **p< 0.01 or *p<0.05 for  
FGF21vs Controls. 
 
A 
B C 
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FGF-21 stimulates mitochondrial respiratory capacity of human 
dopaminergic neurons 
 
To understand if FGF-21 could have effects on mitochondrial functions of human 
dopaminergic neurons we performed a real-time analysis using Searose equipment as 
described above. Our results shown that FGF-21 increased basal respiration and higher 
maximal respiratory capacity in treated cells as compared to controls (Fig 13). These data 
jointly with results about antioxidants, indicate that FGF-21 in human dopaminergic 
neurons can intensify the mitochondrial activity against oxidative stress.  
 
 
 
 
 
 
 
Fig.13- FGF-21 enhances the mitochondrial 
respiratory activity- The mitochondrial 
respiratory capacity in human dopaminergic 
neurons was measured in real-time using the 
Seahorse equipment as described in Methods. 
The basal as well as the maximum respiration 
was improved in cells treated with FGF-21 for 
24h. 
 
  
33 
 
 
 In the light of these results, we wanted to investigate whether treatment with FGF-21 
could affect the number of mitochondria and their biogenesis. To this end we evaluated 
mitochondrial markers such as the mitochondrial transcription factor A (TFAM) and the 
cytochrome oxidase IV (COX IV). Both these markers levels were unchanged in FGF-21 
treated neurons as compared with controls (Fig. 14). 
 
 
 
 
We also estimated the ratio of mitochondrial DNA through quantitative PCR. The 
content of mitochondrial DNA was not changed compared with nuclear DNA, this 
indicate that the number of mitochondria in cells war invariated, after treatment with 
FGF-21. Using Electron Microscopy (EM) we studied also the mitochondrial 
morphology, we substantiate previous data, in fact the measurement of the relative 
mitochondrial area from EM sections not showed significant changes between treated 
with FGF-21, and not treated neuronal samples (Fig 15).  On the basis of these 
observations we can deduce that the increased mitochondrial activity on FGF-21 treated 
human dopaminergic neurons, is not related with an increased number of these organelles 
in the cells.  
 
 
Fig.14- FGF-21 does not 
alter mitochondrial 
biogenesis in dopaminergic 
neurons- Immunoblots. β-
actin was used as control. 
The mitochondrial proteins 
mt-TFA and COX IV were 
no significantly changed in 
dopaminergic neurons treated 
with FGF-21. 
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Mitochondrial surface area. Control and FGF-21 treated cells were analyzed by 
electron microscopy and the relative mitochondrial area was calculated from EM pictures 
as described in Methods. There were no significant changes in the mitochondrial surface 
area between control and FGF-21 treated cells. 
 
 
FGF-21 is expressed in the midbrain and microglia cells 
 
Another important aim for our study was to investigate about the presence of FGF-
21 in the brain. To this end we performed immunoblotting experiment using samples of 
adult rodent brain and antibodies against FGF-21.  Data showed that FGF-21 is expressed 
in several brain areas such as Hippocampus, cortex, striatum and substantia nigra, were 
reside the cell body of dopaminergic neurons (Fig. 16).  
Fig.15- A-B: FGF-21 does not increase the number of mitochondria in dopaminergic neurons- The 
mitochondrial DNA (mt-DNA) copy number was analyzed using quantitative PCR as described in 
Methods. There was no change in the relative ratio of mt-DNA to nuclear DNA reflecting an equal number 
of mitochondria in control and FGF21-treated dopaminergic cells.  Mitochondrial surface area. Control and 
FGF21 treated cells were analyzed by electron microscopy and the relative mitochondrial area was 
calculated from EM pictures as described in Methods. There were no significant changes in the 
mitochondrial surface area between control and FGF-21 treated cells. 
 
A B 
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Immunohistochemical analyses performed with 14 μm sections of midbrain region, 
particularly on the substantia nigra, showed that FGF-21 is also express in these region 
cells (Fig 15). To understand which cell type is involved in the production of FGF-21 in 
the brain, we immunostained midbrain sections using markers for neurons, Tyrosine 
Hydroxylase (TH) to identify dopaminergic neurons, and  glial cells, Glial Fibrillary 
Acidic Protein glial (GFAP). Data showed that neither TH-positive neurons nor GFAP-
positive astrocytes expressed FGF-21 to any significant extent (data not shown). The 
precise localization of FGF-21 became clear after activation of the microglial cells using 
the excitotoxin kainic acid as shown in figure 17. Kainic acid is structurally analog to the 
neurotransmitter glutamate that produces neuroexcitatory agonist effects at the kainite 
ionotropic receptors. The kainate receptors are non-NMDA glutamate-recognizing 
ionotropic receptors, and agonism by Kainic acid or glutamate produces excitation and 
contribution to excitatory postsynaptic currents. 
 
 
 
 
Fig. 16- FGF-21 is expressed  in several Brain areas- 
Brain regions from adult mice were dissected and 
subjected to immunblotting using anti- FGF-21 
antibodies. β-actin was used as control. FGF-21 is present 
in all brain areas. Two bands are detected representing the 
precursor and processed (mature) form of FGF21. SN, 
substantia nigra; ST, striatum; HC. Hippocampus; Cx, 
Cortex. 
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Fig.17- FGF-21 expression in microglial cells of rat brain-  
Immunohistochemical analisys of FGF-21 (green) show its 
expression in microglial cells CD-11 positive (red spots) following 
treatment with Kainic acid.  
Fig.18- FGF-21 is express in microglial cells were made 
from neonatal rat brain. Immunoblotting of cell lysate 
were performed using anti-FGF-21 antibodies. The human 
hepatocytes cell line (Huh7) was used as positive control.  
Note the presence of FGF-21 in microglial and HU7h cells.  
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Agonism of the kainate receptors by sufficient concentrations of Kainic acid 
produces excitotoxicity, and Kainic acid is widely employed as a tool for inducing 
excitotoxic seizures. So the presence of this neurotoxin in brain induced the microglial 
cells activation, and our data shown that FGF-21 co-localized with glial cells positively 
stained for Cd11b (Mac-1) that is a marker for active microglia cells in the brain (Fig. 
17), and its expression increases after a prolonged treatment with the neurotoxin. To 
substantiate this further, microglial cells were cultured from rat brains and analyzed by 
immunoblotting. Results showed that microglia-enriched cultures express FGF-21 in vitro 
in amounts equal to those found in the human hepatocyte Huh7 cell line (Fig. 18). This 
data shows that microglia cells can produce FGF-21 in the midbrain that could then act on 
the dopaminergic neurons to enhance neuronal viability. 
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Discussion 
 
Fibroblast Growth Factor-21 is a member of the FGFs family,  particularly FGF-19 
endocrine sub-family.  It is expressed (in rodents, non-human primates and in humans) 
predominantly in the liver, but also in the adipose tissue, pancreas and muscle. It has been 
studied mainly for its effects on metabolism and cell responses in peripheral cells; in fact 
FGF-21 plays a role in balance energy, exercising hormone-like effects by regulating fatty 
acids metabolism and by regulating in the uptake of glucose, (participating in the 
regulation of expression of insulin and glucagone). Furthermore it also  drew the attention 
of researchers because it can be involved in a several kind of disease, in different tissues 
(liver, hearth, pancreas, kidney). It may be altered, in some cases, and could be 
considered as a diagnostic or prognostic marker of diseases (Woo Y. et al 2013).   
Moreover FGF-21 exerts its functions, also under stress conditions, in several tissues 
inducing the expression of PGC-1α (liver, adipose tissue). Although it has been widely 
studied literature is poor on expression and functions of FGF-21 in the brain. 
PGC-1α is a transcriptional co-activator, and it is considered a major regulator of 
mitochondrial biogenesis, furthermore  plays an important role regulating gene expression 
of antioxidant mitochondrial enzymes, it is express in several tissues including CNS. 
Importantly our research group, lately demonstrate, that PGC-1α is able to confer 
neuroprotective effects in dopaminergic neurons, on Parkinson’s Disease animal model 
(Mudò et. al 2012). In the present work we  investigated about possible interactions 
between FGF-21 and PGC-1α, in human dopaminergic neurons. To this end we used 
human neuronal precursors, grown in appropriate medium and conditions to induce 
differentiation into dopaminergic neurons, we treated cells with an adequate dose of FGF-
21,  and after 24 hours we found an increase of PGC-1α protein  expression; we also 
found enhanced the PGC-1α gene promoter activity, this suggest that the FGF-21 action 
on PGC-1α is not restricted to metabolic tissues but can act, regulating both the 
transcription and the production of the protein, also in the brain.   
We also observed that the increase of PGC-1α is probably related with the increase 
of mitochondrial activity in neurons. In fact after the  FGF-21 treatment we found 
increased levels of antioxidant mitochondrial enzymes such as Trx2 and Sod2, indicating 
an enhanced mitochondrial activity, these data also confirm a previous study in which, 
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using transgenic mice overespressing PGC-1α, we demonstrate the ability of PGC-1α to 
induce the expression of molecules against oxidative stress, and this action can be 
considered part of its neuroprotective effect. PGC-1α also takes part in protection against 
cell stress and oxidative damage accompanying human metabolic disorders and 
degenerative diseases (St-Pierre et al., 2006).  As shown in vivo, the increase in 
mitochondrial antioxidants by PGC-1α was accompanied by cell protection of 
dopaminergic neurons against the neurotoxin MPTP induced oxidative stress (Mudò et 
al., 2012).  Together these results show that PGC-1α is an important factor in regulation 
of dopaminergic neuron viability and that growth factors like FGF-21 may act via the 
induction of PGC-1α and its downstream pathways in these neurons, participating to these 
beneficial effects. The activity of PGC-1α is regulated through transcriptional and post-
transcriptional events. The most effective and frequent adjustment for this protein is 
operated by the de-acetylase SIRT-1. De-acetylation of specific lysine residues of PGC-
1α, makes it more accessible the binding site to transcriptional factors, then activates the 
protein and capable of carrying out its functions. In our previous study we found that, the 
compound resveratrol acting via the SIRT1/PGC-1α can also stimulate Sod2 and Trx2 
levels both in cultured neurons and in the brain (Mudò et al., 2012). 
Here  we were able to demonstrate by which mechanism FGF-21 can regulate the 
PGC-1α activity. In human dopaminergic neurons, the treatment with FGF-21 also 
induces an increase of SIRT-1 levels, so FGF-21 can induce antioxidant activity trough 
activation  of  SIRT1/PGC-1α pathway. In fact we further observed that the levels of 
NAD
+
 ,the cofactor for SIRT-1, increased in the dopaminergic neurons following FGF-21 
treatments. FGF-21 also elevated the nicotinamidephosphoribosyltransferase (Nampt) 
enzyme levels, that is rate limiting in the biosynthesis of NAD
+
 from nicotinamide 
(NAM) (Revolle et al., 2004; Yang et al., 2007).  Previous studies carried out in vascular 
smooth cells, pancreatic β-cells and in fibroblasts, showed that the enzyme Nampt (also 
called pre-B cell colony-improving factor (PBEF) can be induced by visfatin or by 
reduction of nutrients or by cytokines and that Nampt is involved in regulating metabolic 
responses, inflammation, and cell differentiation in peripheral cells (Garten et al., 2009). 
With ours data we demonstrate that the Nampt-SIRT1 pathway is also active in neurons 
and it can be regulated by FGF-21 signaling, this could reveal of FGF-21 a role  response 
to inflammation also in the Brain. These results in dopaminergic neurons add to previous 
data showing the involvement of Nampt in the biological events described before.  Given 
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its role in the activation of SIRT-1 in dopaminergic neurons it would be interesting to 
study the regulation of Nampt in animal models of PD and after treatment with 
neurotrophic factors. 
Gerhart-Hines et al in 2007 demonstrated that FGF-21 is involved in regulation of 
mitochondrial functions by the SIRT1/ PGC-1α in muscle cells. To establish if FGF-21 
treatment could be able to increase in dopaminergic neurons the mitochondrial activity, 
we performed a real-time assay to measure the mitochondrial respiratory capacity, using 
the Seahorse equipment.  We observed an increased mitochondrial activity, in line with 
previous data mentioned above. Though not formally proven, we suspect that this effect is 
due to the activation of PGC-1α by FGF-21 in these neurons. Subsequently we investigate 
if FGF-21, as a growth factor, could alter the number of mitochondria in the cell. For this 
purpose we analyzed the levels of two mitochondrial markers: COX IV and mt-TFA 
respectively, protein of the respiratory chain, and transcriptional factor regulator of 
mitochondrial biogenesis; and the mitochondrial DNA copy number using PCR.  Our 
results do not show significant changes in protein levels compared to controls, or in the 
number of the copy of mt-DNA, as compared to the ratio of nuclear DNA. Together these 
data indicate that the increased mitochondrial activity is related to the induction of FGF-
21, rather than to increase the number of organelles. 
It is known that some members of FGFs family are expressed in the brain, like 
FGF-1 FGF-2 but also FGF-13 and FGF-14 and have a role in development and in some 
cases in neuronal diseases (Mudò et al., 2009; Itoh and Ornitz, 2011; Lahti et al., 2012). 
So far little is known about the expression of  FGF-21 in brain or in brain cell 
metabolism. Because of this we wanted to deepen the knowledge of FGF-21 expression in 
the brain.  We performed immunoblotting experiments that shows that FGF-21 in 
expressed   to an appreciable amount in various brain regions of adult mouse, such as 
cortex, Striatum, Hippocampus and Substantia nigra. We used an immunohistochemical 
approach to understand which cell type could express the growth factor. Data highlight 
that FGF-21 was mainly localized to microglial cells, overall in the SN where, moreover, 
the FGF-21 expression is increased after neurotoxic treatment with Kainic acid. This may 
suggest a role of FGF-21 in in response to excitotoxic damage.  These observations open 
up possibilities for new considerations and future studies aimed to understanding what are 
possible the mechanisms underlying the involvement of FGF-21 in response to 
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excitotoxic events, overall in the substantia nigra which is the brain area most damaged in 
Parkinson’s disease.   
Alterations of growth factors are strongly related to metabolic diseases, but also 
may also prevail in neurodegeneration (Patrone et al, 2013). The expression of FGF-21 is 
greatly increased during prolonged fasting, it has several effects on the metabolism, and is 
involved in many metabolic diseases; it is able to pass the blood brain barrier, so can be 
also involved in neurological disorders like PD, or others neurodegenerative diseases. In 
will be interesting in the future also to investigate about its rate of involvement in these 
kind of disorders.   
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Conclusions 
 
We have shown here, that human dopaminergic neurons respond to treatment  with 
Fibroblast Growth Factor 21, increasing the expression and the activity of the 
transcriptional co-activator PGC-1α via SIRT-1, and enhancing the mitochondrial 
respiratory activity, giving greater antioxidant activity. So these effects do not depend by 
the numerical increase in these organelles, rather than by the direct action of FGF-21 on 
PGC-1α. Moreover we observed that FGF-21 is express in both basal and stress 
conditions in several brain areas, particularly in microglial cells, including substantia 
nigra. These results are interesting and suggest that microglia-derived FGF-21 may 
influence dopaminergic and possible also other neurons in the brain. It will be important 
to study in more detail the role of FGF-21 in microglial cells and in neuroimmunological 
responses in the brain and in models of PD. These data together give us more knowledge 
about the physiology of dopaminergic neurons, and emphasizes and supports the 
foundation for understanding of the neuroprotective mechanisms based on PGC-1α 
activity, and open new scenery for future studies, with a possible therapeutic approach of 
neurodegenerative diseases such as PD. 
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